TECX
Tectonic Therapeutic, Inc. · Healthcare
Insiders bought $130K of Tectonic Therapeutic, Inc. in the last 12 months
1 insider bought on 1 day.
TECX over the last year
Largest buyers, last 12 months
TECX after insider buys
3 months after each buy, from the first price a copier could get.
5 buys since 2024 with 3 months of prices.
Every filing
6 insider filings since 2024, newest first
Daniel Lochner · CFO
Timothy A Springer · Director and 10% owner
Timothy A Springer · Director and 10% owner
Timothy A Springer · Director and 10% owner
Daniel Lochner · CFO
Timothy A Springer · Director and 10% owner
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.